BJDX Stock Price, Bluejay Diagnostics, . Quote, Chart

Market Summary

USD0.550.00

Delayedas of 30 Apr 2024, 02:05 pm

0.00%

BJDX Stock Price

View Fullscreen

BJDX RSI Chart

BJDX Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

3.98

Price/Free Cashflow

-0.16

BJDX Price/Sales (Trailing)

BJDX Profitability

Return on Equity

-343.85%

Return on Assets

-204.45%

Free Cashflow Yield

-609.88%

BJDX Fundamentals

BJDX Revenue

BJDX Earnings

Earnings (TTM)

-10.0M

Earnings Growth (Yr)

3.5%

Earnings Growth (Qtr)

-0.21%

Breaking Down BJDX Revenue

52 Week Range

0.58

(Low)(High)

Last 7 days

-11.3%

Last 30 days

-31.2%

Last 90 days

-32.1%

Trailing 12 Months

-90.8%

How does BJDX drawdown profile look like?

BJDX Financial Health

Current Ratio

1.82

BJDX Investor Care

Shares Dilution (1Y)

22.98%

Diluted EPS (TTM)

-9.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q2	Q3	Q4
2023	0	0	0
2022	133.0K	191.0K	249.0K
2021	0	0	75.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Bluejay Diagnostics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 13, 2023	dey indranil	bought	1,635	3.27	500	president and ceo
Dec 13, 2023	dey svetlana	bought	1,535	3.07	500	-
Mar 28, 2023	dey indranil	bought	880	0.44	2,000	president and ceo
Mar 28, 2023	dey indranil	acquired	880	0.44	2,000	president and ceo
Mar 27, 2023	dey indranil	bought	3,520	0.44	8,000	president and ceo
Mar 27, 2023	dey indranil	acquired	3,520	0.44	8,000	president and ceo
Mar 24, 2023	dey svetlana	bought	4,400	0.44	10,000	-
Mar 24, 2023	dey svetlana	acquired	4,400	0.44	10,000	-
Feb 01, 2023	wurth douglas clark	acquired	12,100	0.44	27,500	-
Feb 01, 2023	gemignani gary g	acquired	12,100	0.44	27,500	-

Which funds bought or sold BJDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	26,824	26,824	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	added	606	91,023,000	182,910,000	0.18%
Feb 14, 2024	Coppell Advisory Solutions LLC	sold off	-100	-674	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	125	-2,268	3,967	-%
Feb 13, 2024	ARMISTICE CAPITAL, LLC	new	-	29,561	29,561	-%
Feb 12, 2024	JPMORGAN CHASE & CO	reduced	-71.09	-840	74.00	-%
Feb 12, 2024	OSAIC HOLDINGS, INC.	unchanged	-	-78.00	30.00	-%
Feb 09, 2024	WELLS FARGO & COMPANY/MN	added	50.00	-10.00	7.00	-%
Feb 07, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%

Are Funds Buying or Selling BJDX?

Are funds buying BJDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BJDX

No. of Funds

Unveiling Bluejay Diagnostics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	194,525	SC 13G
Jan 03, 2024	sabby management, llc	9.99%	177,513	SC 13G

Recent SEC filings of Bluejay Diagnostics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	DEF 14A	DEF 14A
Apr 05, 2024	PRE 14A	PRE 14A
Apr 02, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 04, 2024	8-K	Current Report
Feb 14, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Bluejay Diagnostics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.1B	40.1B	-5.62%	-2.90%	32.52	4.64	-8.12%	-17.45%
BDX	67.4B	19.5B	-5.66%	-11.68%	53.7	3.46	4.02%	-22.04%
ALGN	22.9B	3.9B	-7.04%	-6.30%	51.44	5.93	3.42%	23.09%
BAX	20.6B	14.8B	-4.91%	-14.77%	7.77	1.39	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	1.73%	23.52%	30.36	2.68	6.16%	35.06%
HSIC	9.4B	12.3B	-3.30%	-9.63%	22.56	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-19.88%	-38.53%	-12.7	3.03	-4.68%	82.43%
XRAY	6.4B	4.0B	-7.53%	-26.81%	-47.32	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-2.96%	16.48%	-560.62	9.29	33.86%	89.83%
PDCO	2.3B	6.6B	-5.97%	-4.09%	12.04	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.99%	-14.73%	-1.99	0.42	7.73%	-1066.14%
ANIK	379.2M	166.7M	2.24%	1.21%	-4.59	2.28	6.67%	-456.34%
ANGO	233.1M	324.0M	-0.85%	-30.05%	-1.21	0.72	-3.19%	-337.41%
APYX	48.5M	52.3M	2.94%	-58.82%	-2.59	0.93	17.61%	19.28%
AEMD	3.6M	3.7M	-18.45%	260.53%	-0.29	0.96	5.77%	8.23%

Bluejay Diagnostics, Inc. News

Latest updates

Bluejay Diagnostics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2
Revenue	-	-	-	-	249,040	191,027	133,013	75,000
Gross Profit	-	-	-	-	48,911	-	-	-
Operating Expenses	-2.7%	2,386,724	2,453,612	2,810,178	2,034,636	1,372,905	957,988	666,072
S&GA Expenses	-99.6%	687	170,277	146,102	81,357	99,961	70,411	50,250
R&D Expenses	-2.6%	1,286,451	1,321,447	1,379,665	756,283	455,253	442,527	225,992
Interest Expenses	-	-	-	-	-	-97,914	-237,429	-59,167
Net Income	3.5%	-2,302,742	-2,386,254	-2,959,889	-1,937,402	-2,100,729	-1,193,381	640,233
Net Income Margin	-7.1%	-39.97	-37.33	-47.17	-54.47	-37.97	-	-
Free Cashflow	10.0%	-2,865,371	-3,182,450	-2,052,497	-1,782,315	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet											(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-41.0%	4,869	8,247	8,478	10,888	13,521	15,706	18,067	20,081	21,019	3,623	1,517
Current Assets	-50.7%	3,221	6,528	6,582	8,902	11,788	13,936	17,050	19,320	20,660	3,264	1,058
Cash Equivalents	-56.5%	2,209	5,077	5,100	6,782	10,115	13,289	15,342	17,124	19,048	2,330	912
Inventory	-	-	-	-	-	-	-	671	893	-	-	85.00
Net PPE	-2.7%	1,286	1,322	1,464	1,520	1,232	1,238	409	344	337	359	459
Liabilities	-34.9%	1,974	3,033	2,102	1,725	1,980	1,895	1,410	1,592	637	4,704	1,845
Current Liabilities	-36.7%	1,771	2,800	1,833	1,420	1,640	1,523	980	1,309	637	-	-
Shareholder's Equity	-44.5%	2,895	5,213	6,376	9,163	11,541	13,811	16,658	18,489	20,382	-	-
Retained Earnings	-9.3%	-26,950	-24,648	-22,350	-19,536	-16,997	-14,610	-11,650	-9,713	-7,694	-6,234	-4,206
Additional Paid-In Capital	-0.1%	29,846	29,861	28,726	28,698	28,538	28,420	28,307	28,201	28,074	5,152	-
Shares Outstanding	0%	1,239	1,239	1,023	1,023	1,011	1,008	1,007	1,007	1,006	525	157
Float	-	-	-	3,030	-	-	-	21,361	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-146.9%	-2,777	-1,125	-1,477	-2,933	-2,944	-1,261	-1,659	-1,877	-2,523	-1,114	-356	-372	-	-
Share Based Compensation	63.4%	-15.56	-42.48	28.00	220	88.00	113	106	126	22.00	47.00	155*	164*	-680*	6.00
Cashflow From Investing	-18.0%	-87.89	-74.50	-201	-340	-238	-791	-123	-46.35	-	-	-	-	-	-
Cashflow From Financing	-100.3%	-3.05	1,176	-2.68	-58.80	-	-	-	-	19,258	1,049	2,510	-290	-	-
Buy Backs	-	-	-	1.00	58.00	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BJDX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue		$ 249,040
Cost of sales		200,129
Gross profit		48,911
Operating expenses:
Research and development	5,714,574	4,152,152
General and administrative	4,313,200	4,763,114
Sales and marketing	283,443	451,421
Total operating expenses	10,311,217	9,366,687
Operating loss	(10,311,217)	(9,317,776)
Other income (expense):
Impairment of property and equipment		(237,309)
Interest income	164,900	89,673
Other income, net	192,429	168,464
Total other income	357,329	20,828
Net loss	$ (9,953,888)	$ (9,296,948)
Net loss per share - Basic (in Dollars per share)	$ (9.08)	$ (9.22)
Weighted average common shares outstanding:
Weighted average common shares outstanding Basic (in Shares)	1,096,500	1,008,196

BJDX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,208,516	$ 10,114,990
Prepaid expenses and other current assets	747,263	1,673,480
Deferred offering costs	265,081
Total current assets	3,220,860	11,788,470
Property and equipment, net	1,285,741	1,232,070
Operating lease right-of-use assets	333,267	465,514
Other non-current assets	28,663	35,211
Total assets	4,868,531	13,521,265
Current liabilities:
Accounts payable	491,474	635,818
Operating lease liability, current	162,990	168,706
Accrued expenses	1,116,911	835,730
Total current liabilities	1,771,375	1,640,254
Operating lease liability, non-current	189,987	323,915
Other non-current liabilities	12,321	15,823
Total liabilities	1,973,683	1,979,992
Commitments and contingencies (Note 9)
Stockholders’ equity:
Common stock, $0.0001 par value; 7,500,000 shares authorized; 1,239,140 and 1,010,560 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	124	101
Additional paid-in capital	29,845,714	28,538,274
Accumulated deficit	(26,950,990)	(16,997,102)
Total stockholders’ equity	2,894,848	11,541,273
Total liabilities and stockholders’ equity	$ 4,868,531	$ 13,521,265

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

CEO	Mr. Indranil Dey
WEBSITE	bluejaydx.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	16

Bluejay Diagnostics, Inc. Frequently Asked Questions

What is the ticker symbol for Bluejay Diagnostics, Inc.? What does BJDX stand for in stocks?

BJDX is the stock ticker symbol of Bluejay Diagnostics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bluejay Diagnostics, Inc. (BJDX)?

As of Mon Apr 29 2024, market cap of Bluejay Diagnostics, Inc. is 1.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BJDX stock?

You can check BJDX's fair value in chart for subscribers.

What is the fair value of BJDX stock?

You can check BJDX's fair value in chart for subscribers. The fair value of Bluejay Diagnostics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bluejay Diagnostics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BJDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bluejay Diagnostics, Inc. a good stock to buy?

The fair value guage provides a quick view whether BJDX is over valued or under valued. Whether Bluejay Diagnostics, Inc. is cheap or expensive depends on the assumptions which impact Bluejay Diagnostics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BJDX.

What is Bluejay Diagnostics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, BJDX's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 3.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BJDX PE ratio will change depending on the future growth rate expectations of investors.